| |
A SPECIAL
ANNOUNCEMENT FROM: |
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Otic Chronicle
A Guide to Conducting Nonclinical Safety Studies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Developments
for new therapeutics to target various aspects of auditory system
dysfunction is on the rise within the drug development industry, as
developers seek to combat otic disorders that inhabit the processing of
appropriate auditory responses. Join Rachel as she reviews nonclinical
auditory safety programs.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Register now to hear from your presenter for the upcoming webinar, The Otic Chronicle | A guide to Conducting Nonclinical Safety Studies, on Thursday, August 17 at 10 AM EDT. |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rachel will address
- Otic therapeutics within the drug development industry
- Commonly asked questions regarding timelines & species |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rachel Tapp, MS, LATG,
is a Senior Study Director for neurobehavioral sciences at MPI
Research. As an expert with more than 15 years of experience, she
ensures high level performance of regulatory and non-regulatory
contracted neurobehavioral ototoxicity studies, focusing on study
management, communication, and fostering Sponsor relationships.She has
authored many auditory safety posters and articles and is an active
member of the Association for Research in Otolaryngology, the Society
for Neuroscience, and the Safety Pharmacology Society. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
